Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1097 - Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma

Date

09 Sep 2017

Session

Poster display session

Presenters

Yusuke Okuma

Citation

Annals of Oncology (2017) 28 (suppl_5): v568-v572. 10.1093/annonc/mdx389

Authors

Y. Okuma1, Y. Goto2, F. Ohyanagi3, K. Sunami4, Y. Nakahara1, S. Kitazono3, Y. Tambo3, N. Yanagitani3, S. Kanda2, H. Horinouchi2, A. Horiike3, Y. Fujiwara2, H. Nokihara2, N. Yamamoto2, M. Nishio3, Y. Ohe2, Y. Hosomi1

Author affiliations

  • 1 Department Of Thoracic Oncology And Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, 113-0021 - Tokyo/JP
  • 2 Department Of Thoracic Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 3 Department Of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 135-8550 - Tokyo/JP
  • 4 Department Of Pathology And Clinical Laboratory, National Cancer Center Hospital, 104-0045 - Tokyo/JP
More

Resources

Abstract 1097

Background

Thymic carcinoma (TC) is a rare cancer with minimal evidence of survival with palliative-intent chemotherapy. Sunitinib and everolimus monotherapies have been proposed as active molecular-targeted approaches based on phase II (Ph II) trials, and S-1, an oral fluoropyrimidine, has been described in the NCCN guideline as an active cytotoxic agent for refractory TC based on a case series. Therefore, we conducted a Ph II trial to study the result of S-1 treatment in patients with refractory TC.

Methods

In this Ph II study performed at three cancer centers in Tokyo, we aimed to enroll 26 TC patients previously treated with platinum-based chemotherapy. The patients received S-1 orally twice daily at a dose of 40–60 mg/m2 for 4 weeks, followed by 2 weeks off until progressive disease or unacceptable toxicities. S-1 was used off-label. The primary end-point was determining the objective response rate, and secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicities.

Results

Twenty-six patients (10 males) were recruited between November 2013 and May 2016. The median age was 63 (27–74) years. Among the 26 patients, 23 had squamous cell carcinoma histology and 10 had an ECOG performance status of 0. Additionally, one patient showed complete response and seven patients showed partial responses, resulting in a 30.8% response rate (95% confidence interval [CI], 16.5–50.0) and a 65.4% disease control rate (95% CI, 46.2–80.6). After a median follow-up of 13.4 months, the median PFS was 4.3 months (95% CI, 2.3–7.6 months) and median OS was 23.4 months (95% CI, 12.8–not reached). Treatment-related adverse events (AEs) of grade ≥3 included neutropenia (12%), skin rash (8%), elevated ALT, decreased WBC count, and fatigue (4%). No treatment-related death was observed. However, treatment was discontinued in three patients (12%) because of AEs.

Conclusions

S-1 as palliative-intent chemotherapy and a cytotoxic agent for refractory TC confirmed clinical activity with good tolerability.

Clinical trial identification

UMIN000010736

Legal entity responsible for the study

/National Cancer Center Hospital/The Cancer Institute Hospital of Japanese Foundation for Cancer Research/Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital

Funding

None

Disclosure

Y. Goto, S. Kanda, H. Horinouchi, H. Nokihara, N. Yamamoto, M. Nishio, Y. Ohe: Consulting or Advisory Role from Taiho Pharmaceutical All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.